Key Events This Week
5 Jan: Technical momentum shifts to bullish despite price decline
9 Jan: Sharp 14.8% surge in open interest amid mixed market signals
9 Jan: Week closes at Rs.379.65 (-3.46%)
Feb 03
BSE+NSE Vol: 50.33 lacs

Biocon Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable surge in open interest in its derivatives segment, signalling increased market participation and potential directional bets. The stock outperformed its sector and broader indices, supported by rising volumes and positive price action, prompting a reassessment of its market positioning and investor sentiment.
Read full news article
Biocon Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 October 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.
Read full news article
Biocon Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 12.7% surge in open interest in its derivatives segment, signalling heightened market activity despite the stock’s recent underperformance. This development, coupled with declining price momentum and subdued investor participation, offers a complex picture of market positioning and potential directional bets.
Read full news article
Biocon Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 11.4% surge in open interest in its derivatives segment, signalling heightened market activity despite the stock’s recent underperformance. This development, coupled with declining price momentum and subdued investor participation, suggests a complex positioning landscape that warrants close scrutiny from market participants.
Read full news article
Biocon Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.
Read full news article
5 Jan: Technical momentum shifts to bullish despite price decline
9 Jan: Sharp 14.8% surge in open interest amid mixed market signals
9 Jan: Week closes at Rs.379.65 (-3.46%)

Biocon Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable surge in open interest (OI) in its derivatives segment, signalling increased market activity and shifting investor positioning. This development comes amid a backdrop of mixed price momentum and subdued delivery volumes, raising questions about the underlying directional bets and potential implications for the stock’s near-term trajectory.
Read full news article
Biocon Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 14.02% surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. This increase comes alongside mixed price movements and volume patterns, prompting a closer examination of the underlying market dynamics and potential directional bets.
Read full news article
Biocon Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 13.4% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. This development comes alongside mixed price movements and volume patterns, prompting a closer examination of the underlying market dynamics and potential directional bets.
Read full news articleBiocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates
Biocon Limited has informed the Exchange regarding a press release dated December 02, 2019, titled "Biocon and Mylan Launch Trastuzumab Biosimilar, Ogivri (trastuzumab-dkst), in the U.S.".
Biocon Limited has informed the Exchange regarding a press release dated November 27, 2019, titled "
12 Feb 2026
Biocon Ltd. has declared 10% dividend, ex-date: 04 Jul 25
No Splits history available
Biocon Ltd. has announced 1:1 bonus issue, ex-date: 12 Jun 19
No Rights history available